Erratum to: Specific transfection of inflamed brain by macrophages: A new therapeutic strategy for neurodegenerative diseases(PLoS ONE (2013) 8:4 (e61852) DOI: 10.1371/journal.pone.0061852);Specific Transfection of Inflamed Brain by Macrophages: A New Therapeutic Strategy for Neurodegenerative Diseases

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Haney, Matthew J ^a   Zhao, Yuling ^a   Harrison, Emily B ^a   Mahajan, Vivek ^a,b   Ahmed, Shaheen ^a   He, Zhijian ^a   Suresh, Poornima ^a,b   Hingtgen, Shawn D ^c   Klyachko, Natalia L ^a,d   Mosley, R Lee ^b   Gendelman, Howard E ^b   Kabanov, Alexander V ^a,d   Batrakova, Elena V ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNC Hamner Institute for Drug Safety Sciences   (United States)

^d MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

CATALASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PLASMID DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA MODIFICATION; EXOSOME; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE VECTOR; GENETIC TRANSFECTION; MACROPHAGE; MALE; MOTOR PERFORMANCE; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN SYNTHESIS;

EID: 84876436797     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0306688     Document Type: Erratum

References (62)

1. McGeer PL, Itagaki S, Boyes BE, McGeer EG, (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38: 1285-1291.
2. Busciglio J, Yankner BA, (1995) Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 378: 776-779.
3. Ebadi M, Srinivasan SK, Baxi MD, (1996) Oxidative stress and antioxidant therapy in Parkinson's disease. Prog Neurobiol 48: 1-19.
4. Wu DC, Teismann P, Tieu K, Vila M, Jackson-Lewis V, et al. (2003) NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci U S A 100: 6145-6150.
5. Arends MJ, Wyllie AH, (1991) Apoptosis: mechanisms and roles in pathology. Int Rev Exp Pathol 32: 223-254.
6. Chan PH, (2001) Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab 21: 2-14.
7. Ambani LM, Van Woert MH, Murphy S, (1975) Brain peroxidase and catalase in Parkinson disease. Arch Neurol 32: 114-118.
8. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, et al. (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52: 515-520.
9. Abraham S, Soundararajan CC, Vivekanandhan S, Behari M, (2005) Erythrocyte antioxidant enzymes in Parkinson's disease. Indian J Med Res 121: 111-115.
10. Gonzalez-Polo RA, Soler G, Rodriguezmartin A, Moran JM, Fuentes JM, (2004) Protection against MPP+ neurotoxicity in cerebellar granule cells by antioxidants. Cell Biol Int 28: 373-380.
11. Pappert EJ, Tangney CC, Goetz CG, Ling ZD, Lipton JW, et al. (1996) Alpha-tocopherol in the ventricular cerebrospinal fluid of Parkinson's disease patients: dose-response study and correlations with plasma levels. Neurology 47: 1037-1042.
12. Batrakova EV, Li S, Reynolds AD, Mosley RL, Bronich TK, et al. (2007) A macrophage-nanozyme delivery system for Parkinson's disease. Bioconjug Chem 18: 1498-1506.
13. Brynskikh AM, Zhao Y, Mosley RL, Li S, Boska MD, et al. (2010) Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease. Nanomedicine (Lond) 5: 379-396.
14. Batrakova EV, Gendelman HE, Kabanov AV, (2011) Cell-mediated drug delivery. Expert Opin Drug Deliv 8: 415-433.
15. Zhao Y, Haney MJ, Mahajan V, Reiner BC, Dunaevsky A, et al. (2011) Active Targeted Macrophage-mediated Delivery of Catalase to Affected Brain Regions in Models of Parkinson's Disease. J Nanomed Nanotechnol S4.
16. Haney MJ, Zhao Y, Li S, Higginbotham SM, Booth SL, et al. (2011) Cell-mediated transfer of catalase nanoparticles from macrophages to brain endothelial, glial and neuronal cells. Nanomedicine (Lond) 6: 1215-1230.
17. Zhao Y, Haney MJ, Klyachko NL, Li S, Booth SL, et al. (2011) Polyelectrolyte complex optimization for macrophage delivery of redox enzyme nanoparticles. Nanomedicine (Lond) 6: 25-42.
18. Haney MJ, Suresh P, Zhao Y, Kanmogne GD, Kadiu I, et al. (2012) Blood-borne macrophage-neural cell interactions hitchhike endosome networks for cell-based nanozyme brain delivery. Nanomedicine (Lond) 7: 815-833.
19. Thery C, Amigorena S, Raposo G, Clayton A, (2006) Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol Chapter 3: Unit 3 22.
20. Bhatnagar S, Shinagawa K, Castellino FJ, Schorey JS, (2007) Exosomes released from macrophages infected with intracellular pathogens stimulate a proinflammatory response in vitro and in vivo. Blood 110: 3234-3244.
21. Clayton A, Turkes A, Navabi H, Mason MD, Tabi Z, (2005) Induction of heat shock proteins in B-cell exosomes. J Cell Sci 118: 3631-3638.
22. Nolte-'t Hoen EN, Buschow SI, Anderton SM, Stoorvogel W, Wauben MH, (2009) Activated T cells recruit exosomes secreted by dendritic cells via LFA-1. Blood 113: 1977-1981.
23. Johnstone RM, (1992) The Jeanne Manery-Fisher Memorial Lecture 1991. Maturation of reticulocytes: formation of exosomes as a mechanism for shedding membrane proteins. Biochem Cell Biol 70: 179-190.
24. Zomer A, Vendrig T, Hopmans ES, van Eijndhoven M, Middeldorp JM, et al. (2010) Exosomes: Fit to deliver small RNA. Commun Integr Biol 3: 447-450.
25. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, et al. (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9: 654-659.
26. Thery C, Ostrowski M, Segura E, (2009) Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 9: 581-593.
27. Martinez-Serrano A, Hantzopoulos PA, Bjorklund A, (1996) Ex vivo gene transfer of brain-derived neurotrophic factor to the intact rat forebrain: neurotrophic effects on cholinergic neurons. Eur J Neurosci 8: 727-735.
28. Blurton-Jones M, Kitazawa M, Martinez-Coria H, Castello NA, Muller FJ, et al. (2009) Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A 106: 13594-13599.
29. Akerud P, Canals JM, Snyder EY, Arenas E, (2001) Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease. J Neurosci 21: 8108-8118.
30. Casper D, Engstrom SJ, Mirchandani GR, Pidel A, Palencia D, et al. (2002) Enhanced vascularization and survival of neural transplants with ex vivo angiogenic gene transfer. Cell Transplant 11: 331-349.
31. Yasuhara T, Shingo T, Muraoka K, Kameda M, Agari T, et al. (2005) Neurorescue effects of VEGF on a rat model of Parkinson's disease. Brain Res 1053: 10-18.
32. Biju K, Zhou Q, Li G, Imam SZ, Roberts JL, et al. (2010) Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease. Mol Ther 18: 1536-1544.
33. Martinez-Serrano A, Bjorklund A, (1998) Ex vivo nerve growth factor gene transfer to the basal forebrain in presymptomatic middle-aged rats prevents the development of cholinergic neuron atrophy and cognitive impairment during aging. Proc Natl Acad Sci U S A 95: 1858-1863.
34. Garcia P, Youssef I, Utvik JK, Florent-Bechard S, Barthelemy V, et al. (2010) Ciliary neurotrophic factor cell-based delivery prevents synaptic impairment and improves memory in mouse models of Alzheimer's disease. J Neurosci 30: 7516-7527.
35. Low WC, Lewis PR, Bunch ST, Dunnett SB, Thomas SR, et al. (1982) Function recovery following neural transplantation of embryonic septal nuclei in adult rats with septohippocampal lesions. Nature 300: 260-262.
36. Pizzo DP, Coufal NG, Lortie MJ, Gage FH, Thal LJ, (2006) Regulatable acetylcholine-producing fibroblasts enhance cognitive performance. Mol Ther 13: 175-182.
37. Rosenbaugh EG, Roat JW, Gao L, Yang RF, Manickam DS, et al. (2010) The attenuation of central angiotensin II-dependent pressor response and intra-neuronal signaling by intracarotid injection of nanoformulated copper/zinc superoxide dismutase. Biomaterials 31: 5218-5226.
38. Lyubchenko YL, Shlyakhtenko LS, Gall AA, (2009) Atomic force microscopy imaging and probing of DNA, proteins, and protein DNA complexes: silatrane surface chemistry. Methods Mol Biol 543: 337-351.
39. Henderson RM, Schneider S, Li Q, Hornby D, White SJ, et al. (1996) Imaging ROMK1 inwardly rectifying ATP-sensitive K+ channel protein using atomic force microscopy. Proc Natl Acad Sci U S A 93: 8756-8760.
40. Sena-Esteves M, Tebbets JC, Steffens S, Crombleholme T, Flake AW, (2004) Optimized large-scale production of high titer lentivirus vector pseudotypes. J Virol Methods 122: 131-139.
41. Batrakova EV, Vinogradov SV, Robinson SM, Niehoff ML, Banks WA, et al. (2005) Polypeptide point modifications with fatty acid and amphiphilic block copolymers for enhanced brain delivery. Bioconjug Chem 16: 793-802.
42. Tieu K, Perier C, Caspersen C, Teismann P, Wu DC, et al. (2003) D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J Clin Invest 112: 892-901.
43. Rozas G, Guerra MJ, Labandeira-Garcia JL, (1997) An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res Brain Res Protoc 2: 75-84.
44. Keshet GI, Tolwani RJ, Trejo A, Kraft P, Doyonnas R, et al. (2007) Increased host neuronal survival and motor function in BMT Parkinsonian mice: involvement of immunosuppression. J Comp Neurol 504: 690-701.
45. Papathanou M, Rose S, McCreary A, Jenner P, (2011) Induction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6-OHDA-lesioned rats. Eur J Neurosci 33: 2247-2254.
46. Balkundi S, Nowacek AS, Veerubhotla RS, Chen H, Martinez-Skinner A, et al. (2011) Comparative manufacture and cell-based delivery of antiretroviral nanoformulations. Int J Nanomedicine 6: 3393-3404.
47. Stone DK, Reynolds AD, Mosley RL, Gendelman HE, (2009) Innate and Adaptive Immunity for the Pathobiology of Parkinson's Disease. Antioxid Redox Signal.
48. Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, et al. (2009) Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci 29: 13435-13444.
49. Prasad KN, Cole WC, Hovland AR, Prasad KC, Nahreini P, et al. (1999) Multiple antioxidants in the prevention and treatment of neurodegenerative disease: analysis of biologic rationale. Curr Opin Neurol 12: 761-770.
50. Beal MF, Matthews RT, (1997) Coenzyme Q10 in the central nervous system and its potential usefulness in the treatment of neurodegenerative diseases. Mol Aspects Med 18 Suppl: S169-179.
51. Zhao K, Luo G, Giannelli S, Szeto HH, (2005) Mitochondria-targeted peptide prevents mitochondrial depolarization and apoptosis induced by tert-butyl hydroperoxide in neuronal cell lines. Biochem Pharmacol 70: 1796-1806.
52. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, et al. (2011) Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 29: 341-345.
53. Lakhal S, Wood MJ, (2011) Exosome nanotechnology: an emerging paradigm shift in drug delivery: exploitation of exosome nanovesicles for systemic in vivo delivery of RNAi heralds new horizons for drug delivery across biological barriers. Bioessays 33: 737-741.
54. Zhuang X, Xiang X, Grizzle W, Sun D, Zhang S, et al. (2011) Treatment of Brain Inflammatory Diseases by Delivering Exosome Encapsulated Anti-inflammatory Drugs From the Nasal Region to the Brain. Mol Ther 19: 1769-1779.
55. van den Boorn JG, Schlee M, Coch C, Hartmann G, (2011) SiRNA delivery with exosome nanoparticles. Nat Biotechnol 29: 325-326.
56. Kyritsis AP, Sioka C, Rao JS, (2009) Viruses, gene therapy and stem cells for the treatment of human glioma. Cancer Gene Ther 16: 741-752.
57. Lentz TB, Gray SJ, Samulski RJ, (2012) Viral vectors for gene delivery to the central nervous system. Neurobiol Dis 48: 179-188.
58. Manfredsson FP, Rising AC, Mandel RJ, (2009) AAV9: a potential blood-brain barrier buster. Mol Ther 17: 403-405.
59. Pan D, Gunther R, Duan W, Wendell S, Kaemmerer W, et al. (2002) Biodistribution and toxicity studies of VSVG-pseudotyped lentiviral vector after intravenous administration in mice with the observation of in vivo transduction of bone marrow. Mol Ther 6: 19-29.
60. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, et al. (2009) Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27: 59-65.
61. Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W, Geuze HJ, (2000) Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 113 Pt 19: 3365-3374.
62. Hogan MC, Manganelli L, Woollard JR, Masyuk AI, Masyuk TV, et al. (2009) Characterization of PKD protein-positive exosome-like vesicles. J Am Soc Nephrol 20: 278-288.